Endourage

What Endourage does

Endourage is a privately held pharmaceutical company headquartered in Wheat Ridge, Colorado, developing hemp-derived, indication-specific botanical therapeutics that target the human endocannabinoid system (CB1 and CB2 receptors, with ancillary activity at 5-HT1A, TRPV1, GABA-A, and dopamine signaling). Founded in 2019 by medical doctors, research scientists, and operators, the company has built a product portfolio centered on full-spectrum phytocannabinoid and terpene formulations. Its flagship, Formula C, discloses all 13 cannabinoid and terpene actives at exact mg/mL per serving—CBD, CBG, Δ9-THC, and nine terpenes (linalool, myrcene, limonene, β-caryophyllene, α-humulene, α-bisabolol, and others)—enabling physician-grade drug-drug interaction assessment that distinguishes it from competitors listing only "hemp extract." Endourage's evidence base includes an IRB-approved published randomized controlled trial in Cannabis and Cannabinoid Research (PMID 36252151) showing statistically significant improvements in anxiety (p=0.006), sleep disturbance (p=0.041), and dyspnea (p=0.013), with zero serious adverse events; a Biochemical Pharmacology 2025 study establishing 16 cannabis terpenes as CB1/CB2 partial agonists; and independent citations in BMJ Mental Health, Springer Nature, Frontiers of Medicine, and the University of York. The company has filed an FDA IND application (via subsidiary Front Range Pharmaceuticals) for Protocol FRP-FC4LC-2026, a Phase 2/3 adaptive trial of Formula C for Long COVID enriched for ME/CFS.

The company operates a clinician-focused B2B2C distribution model in which formulations are designed for use by licensed healthcare providers and sold exclusively through a registered clinician portal (clinicians.endourage.com). Products are then recommended to patients under clinical supervision. The portfolio spans therapeutic indications including chronic illness symptom management (Formula C), oncology supportive care (Formula CLR), sleep (Formula ZZZ and ZZZ Extra Strength Gummies), anxiety (Formula AX), depression (Formula DP), opioid reduction (Formula OER), addiction recovery (Formula RE), general wellness (Formula ME), topical applications (Verasome in 30mL and 8oz sizes), and a 2025-launched Detox Support line (Gentle, Regular, Max sublingual drops plus Cream). Pricing is not publicly disclosed; a 10% newsletter signup discount is the only promotional lever referenced. The company maintains a separate R&D entity, Front Range Pharmaceuticals, which holds the FDA IND filing and runs clinical operations, while Endourage, LLC handles OTC commercialization.

Endourage's go-to-market leverages clinical evidence dissemination, a dedicated Clinician Concierge service led by Chief Relationship Officer Chris Lundwall, and emerging integration into CMS Enhancing Oncology Model (EOM) and ACO REACH programs—where qualifying providers may furnish up to $500/year in eligible hemp-derived products to Medicare beneficiaries via the Substance Access BEI. Leadership includes CEO Isaac Foster (20+ years scaling startups including 5 in cannabis/hemp), CMO Dr. Michael Steward (board-certified in family medicine and cannabinoid medicine, disclosed equity holder), and Chairwoman/Co-Founder Lauri Kibby (previously Co-Founder and CFO of Kings Garden, one of California's largest cannabis cultivators). No funding rounds, revenue, or headcount trajectory beyond the 11–50 band are disclosed in available materials.

Name

Endourage

Legal name

Endourage, LLC

Website

https://endourage.com

Company type

Private

Founded year

2019

Operating status

Operating

Headcount range

11–50 employees

Short description

Endourage is a private Wheat Ridge, Colorado pharmaceutical company developing hemp-derived, indication-specific botanical therapeutics targeting the endocannabinoid system, sold exclusively through a clinician portal to patients with chronic illnesses, oncology support needs, and Long COVID symptoms.

Ownership category

akta.pro rank

Product category

Botanical Pharmaceuticals / Hemp-Derived Therapeutics

NAICS

Pharmaceutical Preparation Manufacturing (325412), Medicinal and Botanical Manufacturing (325411)

SIC

Pharmaceutical Preparations (2834), Medicinal Chemicals & Botanical Products (2833)

akta.pro primary industry

Sleep, Stress & Mood OTC (Sleep Aids, Melatonin OTC, Calm/Stress Relief) (CRADAMAJ)

akta.pro secondary industries

Dermatology OTC & Skin Health (Acne Treatments, Eczema/Psoriasis OTC, Antifungals, Wart Removal) (CRADAMAF), Sleep, Stress & Mood Support (HLAIADAG)

Keywords

• Hemp-derived therapeutics
• Cannabinoid formulations
• Botanical pharmaceuticals
• Endocannabinoid therapy
• Clinical hemp CBD

Headquarters

HQ city

Wheat Ridge

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Supply Chain, Personnel, Marketing or Sales, Operations

Revenue model

1. OTC Hemp-CBD Product Sales: Endourage generates revenue through the sale of over-the-counter hemp-derived cannabinoid products including Formula C, Formula CLR, Formula ZZZ, Formula AX, Verasome topical cream, and Detox Support product lines. Products are sold to registered clinicians who recommend them to patients.

Go-to-market motion1 record

Distribution channels2 records

Marketing channels4 records

Core offering

Endourage develops and sells OTC hemp-derived, full-spectrum cannabinoid and terpene formulations (sublingual drops, topical creams, and gummies) targeting the endocannabinoid system for chronic illness symptom management. Products are formulated as indication-specific therapeutics — Formula C for Long COVID/chronic illness, Formula CLR for oncology support, Formula AX for anxiety, Formula ZZZ for sleep, Formula DP for depression, Formula OER for opioid reduction, Formula RE for addiction recovery, plus Verasome topical cream and a Detox Support line — and are sold through registered clinicians who recommend them to patients. The company pursues the FDA Botanical Drug Path, with Front Range Pharmaceuticals having filed an IND application for a Phase 2/3 trial of Formula C.

Product overview

Endourage is a pharmaceutical company developing hemp-derived, indication-specific formulations for clinical use. The product portfolio centers on full-spectrum hemp-CBD sublingual drops and topical preparations designed for clinician recommendation to patients. Core products include Formula C™ (the flagship clinically studied formulation for Long COVID/chronic illness symptoms), Formula CLR™ (oncology support), and the Formula series (AX for anxiety, ZZZ for sleep, DP for depression, OER for opioid reduction, RE for addiction recovery, ME for general wellness). Supporting offerings include Verasome™ topical cream in 30mL and 8oz sizes, ZZZ™ Extra Strength Gummies, and the Detox Support line (Gentle, Regular, Max sublingual drops plus topical Cream). The company positions itself as botanical pharmaceuticals under the FDA Botanical Drug Path, with a focus on full label disclosure of all cannabinoid and terpene actives enabling evidence-based physician recommendations.

Differentiator

Problem solved

Functional benefit

Brands

• Front Range Pharmaceuticals: Pharmaceutical research and development division of Endourage LLC; files Investigational New Drug applications with FDA, conducts clinical trials
• Verasome
• ZZZ
• Formula C
• Formula AX
• Formula OER
• Formula RE
• Formula ME
• Formula CLR
• Formula DP
• Detox Support

Products and services

• Formula C

Quantifiable outcome

• 8 of 9 Long COVID symptoms improved at 56 days (9/9 at 28 days) in IRB-approved published human trial (PMID 36252151)
• +5 more outcomes

Segments4 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

One partnership is on record.

• Front Range PharmaceuticalscoreStrategic or Co-development PartnerFront Range Pharmaceuticals is the pharmaceutical research and development division of Endourage LLC. It conducts FDA regulatory activities including IND filings for clinical trials, maintains the clinical evidence platform, and is responsible for the Phase 2/3 trial of Formula C for Long COVID.

Recent moves6 records

Expansion highlights6 records

Direct peers

• cbdMD: Public CBD brand selling tinctures, topicals, gummies, and sleep/calm SKUs through DTC and retail — comparable in product mix (sleep, calm, topical) and target consumer, with a similar emphasis on broad-spectrum and full-spectrum hemp-CBD formulations.
• Charlotte's Web Holdings: One of the largest U.S. hemp-CBD brands offering full-spectrum and isolate products for sleep, anxiety, recovery, and general wellness — directly comparable in product category, hemp-CBD positioning, and consumer/retail distribution.
• CV Sciences (dba Cizzle Brands): Operator of the PlusCBD Oil brand and developer of a clinical-stage cannabinoid pharmaceutical pipeline — directly comparable as a publicly-traded hemp-CBD brand with pharmaceutical ambitions and clinical evidence strategy similar to Endourage's.
• Medical Marijuana Inc (HempMeds): Pioneer in hemp-derived CBD distribution with a heavy focus on clinical and regulatory positioning, including international cannabis-CBD product distribution — comparable in hemp-CBD focus and clinician-evidence-led GTM.

Broad incumbents

• Canopy Growth: Global cannabis company with consumer CBD/cannabinoid wellness products (e.g., CBD Calm, Sleep) and pharmaceutical R&D — comparable as a broad incumbent with multiple sleep/calm/wellness SKUs and clinical R&D infrastructure.
• Jazz Pharmaceuticals (GW Pharmaceuticals): Acquired GW Pharmaceuticals, the developer of Epidiolex (cannabidiol), the first FDA-approved plant-derived CBD drug — comparable as the most credible pharmaceutical proof-point for the FDA Botanical Drug Path that Endourage is pursuing with Formula C.
• Cronos Group: Public cannabis company with a consumer wellness portfolio including CBD sleep/calm products — comparable in cannabinoid wellness category, with materially larger capital base.
• Tilray Brands: Large publicly-traded cannabis company with consumer/cannabinoid wellness brands and a pharmaceutical division (Tilray Medical) — comparable as a broad incumbent in cannabinoid therapeutics with significantly greater capital and distribution.

Emerging players

• Elixinol Wellness: Hemp-CBD brand with global distribution and an emphasis on clinically tested formulations — comparable as a smaller, science-positioned hemp-CBD peer targeting sleep, stress, and pain.
• Level Select / Level Brands (cbdMD's clinical arm): Hemp-CBD brand with practitioner-channel distribution and clinical positioning, similar to Endourage's clinician-only portal and B2B2C model — comparable in targeting healthcare providers and chronic symptom use cases.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat5 records

Key risks6 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/endourage

Revenue estimate

Valuation estimate

Number of profiles

Profiles9 records

Subsidiaries1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Endourage